GSK plc Sponsored ADR (GSK)
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any value from the new drug is unlikely to materialise for shareholders in the near term. The bank maintains its 'neutral' rating on GSK after trial results for the company's experimental drug bepirovirsen were published in the New England Journal of Medicine.
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral pills.
Here's Why GSK (GSK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China.
Why GSK (GSK) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK (GSK) Tops Q1 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.
